Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HKDC1 | Q2TB90 | 3/20 | 0.54 |
| ▸ | TOP2A | P11388 | 2/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9938465 | 0.99 | HKDC1 (0.53) | HKDC1TOP2AAGTR1HTTLMNA | |
| SCHEMBL13522811 | 0.92 | HKDC1 (0.65) | HKDC1TOP2AAGTR1HTTLMNA | |
| SCHEMBL1025308 | 0.85 | HKDC1 (0.55) | HKDC1TOP2AAGTR1HTTLMNA | |
| SCHEMBL29404209 | 0.85 | HKDC1 (0.55) | HKDC1TOP2AAGTR1HTTLMNA | |
| SCHEMBL29506909 | 0.78 | HKDC1 (0.67) | HKDC1TOP2AAGTR1HTTLMNA | |
| SCHEMBL881251 | 0.78 | HKDC1 (0.67) | HKDC1TOP2AAGTR1HTTLMNA | |
| SCHEMBL12955842 | 0.77 | TOP2A (0.56) | HKDC1TOP2AAGTR1HTTSMN1; SMN2 | |
| SCHEMBL1025639 | 0.77 | TOP2A (0.77) | HKDC1TOP2AAGTR1HTTLMNA | |
| SCHEMBL31690659 | 0.77 | TOP2A (0.59) | HKDC1TOP2AAGTR1HTTSMN1; SMN2 | |
| SCHEMBL10697881 | 0.76 | TOP2A (0.49) | HKDC1TOP2AHTTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3125920-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | Del Mar Pharmaceuticals (CA) | 2017-02-08 | — | — | EP | claimed |
| WO-2015154064-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2015-10-08 | — | — | WO | claimed |
| US-8927580-B2 | Thiosemicarbazone compounds and use in the treatment of cancer | Oncochel Therapeutics LLC (US) | 2015-01-06 | — | — | US | claimed |
| US-20140206725-A1 | THIOSEMICARBAZONE COMPOUNDS AND USE IN THE TREATMENT OF CANCER | ONCOCHEL THERAPEUTICS, LLC | 2014-07-24 | — | — | US | claimed |
| EP-2651894-A1 | THIOSEMICARBAZONE COMPOUNDS AND USE IN THE TREATMENT OF CANCER | Richardson, Des R (AU) | 2013-10-23 | — | — | EP | claimed |
| WO-2012079128-A1 | THIOSEMICARBAZONE COMPOUNDS AND USE IN THE TREATMENT OF CANCER | RICHARDSON DES R (AU) | 2012-06-21 | — | — | WO | claimed |
| WO-2024124297-A1 | ANTI-CANCER COMPOUNDS AND USES THEREOF | GRIFFITH UNIVERSITY (AU) | 2024-06-20 | — | — | WO | disclosed |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2023-01-03 | — | — | US | disclosed |
| CN-106659765-B | Use of dianhydrogalactitol and analogs or derivatives thereof for treating non-small cell lung cancer and ovarian cancer | 德玛医药 | 2021-08-13 | — | — | CN | disclosed |
| EP-3125920-B1 | DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL OR DIBROMODULCITOL TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2020-12-23 | — | — | EP | disclosed |
| US-20190269646-A9 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2019-09-05 | — | — | US | disclosed |
| US-20190000850-A1 | COMBINATION CANCER THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-01-03 | — | — | US | disclosed |
| US-20180140571-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | BACHA JEFFREY (CA) | 2018-05-24 | — | — | US | disclosed |
| US-8927580-B2 | Thiosemicarbazone compounds and use in the treatment of cancer | Oncochel Therapeutics LLC (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927580-B2 | Thiosemicarbazone compounds and use in the treatment of cancer | Oncochel Therapeutics LLC (US) | 2015-01-06 | — | — | US | disclosed |
| US-20140206725-A1 | THIOSEMICARBAZONE COMPOUNDS AND USE IN THE TREATMENT OF CANCER | ONCOCHEL THERAPEUTICS, LLC | 2014-07-24 | — | — | US | disclosed |
| US-20140206725-A1 | THIOSEMICARBAZONE COMPOUNDS AND USE IN THE TREATMENT OF CANCER | ONCOCHEL THERAPEUTICS, LLC | 2014-07-24 | — | — | US | disclosed |
| US-20140206725-A1 | THIOSEMICARBAZONE COMPOUNDS AND USE IN THE TREATMENT OF CANCER | ONCOCHEL THERAPEUTICS, LLC | 2014-07-24 | — | — | US | disclosed |
| EP-2651894-A1 | THIOSEMICARBAZONE COMPOUNDS AND USE IN THE TREATMENT OF CANCER | Richardson, Des R (AU) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012079128-A1 | THIOSEMICARBAZONE COMPOUNDS AND USE IN THE TREATMENT OF CANCER | RICHARDSON DES R (AU) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206725-A1 | THIOSEMICARBAZONE COMPOUNDS AND USE IN THE TREATMENT OF CANCER | ETV6, TPMT, ABCB1 | HKDC1 1474/4885TOP2A 100/4885AGTR1 1749/4885 |
| US-20190269646-A9 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DNMT1, MGMT, DCK | HKDC1 1217/4885TOP2A 20/4885AGTR1 4414/4885 |
| US-20180140571-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DNMT1, MGMT, DCK | HKDC1 1217/4885TOP2A 20/4885AGTR1 4414/4885 |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DNMT1, MGMT, DCK | HKDC1 1217/4885TOP2A 20/4885AGTR1 4414/4885 |
| US-20190000850-A1 | COMBINATION CANCER THERAPY | TP53, MCL1, TOP2A | HKDC1 206/4885TOP2A 3/4885AGTR1 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.